Quotient Clinical expands GMP manufacturing capacity
To meet demand for its RapidFACT service
Quotient Clinical, a division of UK drug development services provider Quotient Bioresearch, has completed a major expansion of its Pharmaceutical Sciences facilities in Nottingham, UK.
The firm’s GMP manufacturing suite has doubled in size and now incorporates six independent manufacturing rooms supporting oral, inhaled and parenteral drug products. The formulation development and pharmaceutical analysis laboratory areas have also been significantly increased and now occupy a purpose-built facility of 11,000ft2.
The new facilities have been inspected and approved for use by the UK Medicines and Healthcare products Regulatory Agency, and are now fully operational.
The expansion is in response to increasing demand for Quotient's RapidFACT (Rapid Formulation development And Clinical Testing) service. RapidFACT enables the efficient investigation and optimisation of new drug product formulations in humans.
The company says RapidFACT reduces conventional development timelines by 50–60% and API consumption by up to 90%. It is also effective in addressing the clinical problems associated with poorly soluble drugs or identifying optimal exposure profiles from modified release formulations.
Mark Egerton, managing director of Quotient Clinical, said: ‘Following the recent announcement of our collaboration agreement with Bend Research, the completion of our Pharmaceutical Sciences laboratory and GMP expansion is a milestone achievement, representing a further significant investment in our RapidFACT service.’